Analyzing Oncogenes and Resistance in Lung Cancer
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers
This study is trying to find out how certain changes in lung cancer tumors affect how well treatments work, so doctors can make better decisions for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Trial ID | NCT01580982 on ClinicalTrials.gov |
What this trial studies
This study focuses on understanding the mechanisms of sensitivity and resistance to oncogene-targeted therapies in patients with lung and other thoracic cancers. It involves collecting tumor tissue samples from patients undergoing treatment or investigation for these cancers, particularly when there is suspected tumor progression. The goal is to identify somatic changes in the tumor tissue that may influence subsequent treatment decisions based on molecular analysis of the samples.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18 and older who are being treated for thoracic cancers and undergoing procedures that provide tumor samples for analysis.
Not a fit: Patients who are not undergoing oncogene-targeted therapies or do not have accessible tumor samples may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with lung cancer.
How similar studies have performed: Other studies have shown success in using molecular analysis to guide treatment decisions in cancer, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies 2. Aged 18 years or older 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis. 4. Patients must have the ability to understand and willingness to sign an informed consent document. Exclusion Criteria: \-
Where this trial is running
Aurora, Colorado
- University of Colorado Cancer Center — Aurora, Colorado, United States (Recruiting)
Study contacts
- Principal investigator: Erin Schenk, MD, PhD — University of Colorado, Denver
- Study coordinator: Brandi Kubala
- Email: brandi.kubala@cuanschutz.edu
- Phone: 303-724-1657
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.